X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The primary objective of the study is to evaluate the safety and tolerability of intravenous dosing of PulmoStem (amniopul-02) in patients with severe lower respiratory tract infections, including COVID-19, Influenza A, Metapneumovirus and Respiratory Syncytial Virus (RSV).
Lead Product(s): PulmoStem
Therapeutic Area: Infections and Infectious Diseases Product Name: AmnioPul-02
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.
Lead Product(s): PulmoStem
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PulmoStem
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
